Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Apr;45(2):187-199.
doi: 10.1055/s-0043-1778641. Epub 2024 Feb 1.

Antibiotic Strategies for Severe Community-Acquired Pneumonia

Matteo Bassetti  1   2 , Daniele R Giacobbe  1   2 , Laura Magnasco  1   2 , Alberto Fantin  3 , Antonio Vena  1   2 , Nadia Castaldo  3
Affiliations
Review

Antibiotic Strategies for Severe Community-Acquired Pneumonia

Matteo Bassetti et al. Semin Respir Crit Care Med. 2024 Apr.

Abstract

Despite advancements in health systems and intensive care unit (ICU) care, along with the introduction of novel antibiotics and microbiologic techniques, mortality rates in severe community-acquired pneumonia (sCAP) patients have not shown significant improvement. Delayed admission to the ICU is a major risk factor for higher mortality. Apart from choosing the appropriate site of care, prompt and appropriate antibiotic therapy significantly affects the prognosis of sCAP. Treatment regimens involving ceftaroline or ceftobiprole are currently considered the best options for managing patients with sCAP. Additionally, several other molecules, such as delafloxacin, lefamulin, and omadacycline, hold promise as therapeutic strategies for sCAP. This review aims to provide a comprehensive summary of the key challenges in managing adults with severe CAP, focusing on essential aspects related to antibiotic treatment and investigating potential strategies to enhance clinical outcomes in sCAP patients.

PubMed Disclaimer

Conflict of interest statement

Outside the submitted work, M.B. reports research grants and/or advisor/consultant and/or speaker/chairman fees from Bayer, BioMerieux, Cidara, Cipla, Gilead, Menarini, MSD, Pfizer, Shionogi, and Tillotts Pharma. Outside the submitted work, D.R.G. reports investigator-initiated grants from Pfizer, Shionogi, and Gilead Italia, and speaker and/or advisory board fees from Pfizer and Tillotts Pharma. Outside of the submitted word A.V. reports research grants and/or advisor/consultant and/or speaker/chairman fees from Gilead, Menarini, MSD, Pfizer, Tillotts Pharma, and Shionogi. The other authors have no conflicts of interest to declare.

Substances